Hungarian national amyloidosis study
Part of Brain & nervous system, Cancer, Genetic & congenital, Hormones & metabolism, Immune system & allergy clinical trials.
This study creates a registry for people diagnosed with systemic amyloidosis in Hungary. It helps doctors better understand the condition by collecting medical history and tracking outcomes over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with systemic amyloidosis
- You are 18 years or older
- You can give your consent to participate
- Your doctor agrees to your participation
- Your medical records are available for review
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood and tissue samples and health data from people with amyloidosis to build a biobank and registry. Researchers hope this will help improve future diagnosis and treatment.
This trial builds an Italian online network to learn from people who may have amyloidosis (an abnormal protein condition). It collects information from participating centers and could help doctors better understand different types of amyloidosis.
This trial is a registry that collects health information from people with amyloidosis, including cases where the heart may be involved. Sharing your medical details can help researchers learn how this condition affects patients and may guide future care.
This study collects information and samples from people newly diagnosed with AL amyloidosis who have not yet received treatment. It aims to improve how this rare disease is diagnosed and managed across Europe.
This study collects information from adults with systemic AL amyloidosis to better understand the disease and outcomes. Because it includes pre-treatment records and follows people over time, it may help future patients by improving knowledge of how AL amyloidosis progresses and responds to care.
This is an observational study (no study drug) for people with transthyretin (TTR)–mediated amyloidosis, including people who carry certain gene changes before symptoms begin. It may help researchers better understand how the disease affects health over time and what to measure in future treatments.
Hear when a new Systemic Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.